Skip to main content
SpringerLink
Log in

Chronotherapeutics: Are there meaningful differences among antihypertensive drugs?

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

In the past decade, many publications have dealt with the possible relationship between biological rhythms and the incidence of cardiovascular events. A high proportion of treated hypertensive patients have cardiovascular complications, and chronotherapy, which permits the use of drugs that are maximally effective at different points in the circadian cycle, may be an interesting and valuable approach t decreasing morbidity and mortality in these patients. This article summarizes current knowledge on the new science of chronopharmacology, as demonstrated in several clinical studies that have used conventional agents administered at various points in the circadian cycle as well as new chronotherapeutic agents, such as controlled onset extended release (COER)-verapamil. In addition, emphasis is given to a rigorous evaluation of antihypertensive agents in terms of efficacy and duration of effect to obtain adequate and sustained lowering of blood pressure over the 24-hour period.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Lemmer B, Labrecque G: Chronopharmacology and chronotherapeutics: definitions and concepts. Chronobiol Int 1987, 4:319–329.

    PubMed  CAS  Google Scholar 

  2. Levi F: Biological rhythms, chronotherapy and nitrates. Ann Cardiol Angeiol 1997, 46:426–430.

    CAS  Google Scholar 

  3. Smolensky MH: Chronobiology and chronotherapeutics: applications to cardiovascular medicine. Am J Hypertens 1996, 9:11S-21S. Addresses the current aspects of knowledge and research on chronobiology and chronotherapeutics. Will help the reader to learn the theoritical basis of chronobiology and to see the future applications of this new science in cardiovascular therapy.

    PubMed  CAS  Google Scholar 

  4. Smolensky MH: Knowledge and attitudes of American physicians and public about medical chronobiology and chronotherapeutics: findings of two 1996 Gallup surveys. Chronobiol Int 1998, 15:377–394.

    Article  PubMed  CAS  Google Scholar 

  5. Mulcahy D, Keegan J, Cunningham D, et al.: Circadian variation of total ischemic burden and its alteration with antianginal agents Lancet 1988, 2:755–759.

    Article  PubMed  CAS  Google Scholar 

  6. Fox K, Mulcahy D, Keegan J, et al.: Circadian patterns of myocardial ischemia. Am Heart J 1989, 118:1084–1087.

    Article  PubMed  CAS  Google Scholar 

  7. Argentino C, Toni D, Rasura M, et al.: Circadian variation in the frequency of ischemic stroke. Stroke 1990, 12:387–389.

    Article  Google Scholar 

  8. Marler JR, Price TR, Clark GL, et al.: Morning increase in onset of ischemic stroke. Stroke 1989, 20:473–476.

    PubMed  CAS  Google Scholar 

  9. Willich SN, Levy D, Rocco MB, et al.: Circadian variation in the incidence of sudden cardiac death in the Framingham Heart Study population. Am J Cardiol 1987, 60:801–806.

    Article  PubMed  CAS  Google Scholar 

  10. Muller JE, Stone PH, Turi ZG, et al.: Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 1985, 313:1315–1322.

    Article  PubMed  CAS  Google Scholar 

  11. Muller JE, Toffler GH, Stone PH: Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989, 79:733–743.

    PubMed  CAS  Google Scholar 

  12. Staessen J, Bulpitt CJ, O’Brien E, et al.: The diurnal blood pressure profile: a population study. Am J Hypertens 1992, 5:386–392.

    PubMed  CAS  Google Scholar 

  13. Punzi HA: Why ambulatory blood pressure monitoring? Am J Health Syst Pharm 1998, 55:S12-S16.

    PubMed  Google Scholar 

  14. Waeber B, Rutschmann B, Nüssberger J, et al.: Evaluation of antihypertensive therapy: discrepancies between office and ambulatory recorded blood pressure. J Hypertens 1991, 9:S53-S56.

    CAS  Google Scholar 

  15. The Scientific Committee: Consensus document on noninvasive ambulatory blood pressure monitoring. J Hypertens 1990, 8:S135-S140.

    Google Scholar 

  16. Neutel J, Smith D, Ram C: Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. Am J Med 1993, 94:181–187.

    Article  PubMed  CAS  Google Scholar 

  17. Verdecchia P, Porcellati C, Schillaci G: Ambulatory blood pressure: an independant predictor of prognosis in essential hypertension. Hypertension 1994, 24:793–801.

    PubMed  CAS  Google Scholar 

  18. Perloff D, Sokolow M, Cowan R, et al.: Prognostic value of ambulatory blood pressure measurements: further analyses. J Hum Hypertens 1989, 7:S3-S10.

    CAS  Google Scholar 

  19. Perloff D, Sokolow M, Cowan R: The prognostic value of ambulatory blood pressure. JAMA 1983, 249:2792–2798.

    Article  PubMed  CAS  Google Scholar 

  20. Mancia G, Zanchetti A, Agebiti-Rosei E, et al.: Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Circulation 1997, 95:1464–1470.

    PubMed  CAS  Google Scholar 

  21. Timio M, Lalli S, Venanzi S: Renal damage and night-time blood pressure in uremic, treated hypertensive patients: a 3 years prospective study. Proceedings of the Sixth European Meeting on Hypertension: 4-7 June 1993, Milan. J Hypertens 1993, 11:S490.

    Article  Google Scholar 

  22. White WB, Mehrotra DV, Black HR, et al.: Effects of controlledonset extended-release verapamil on nocturnal blood pressure (dippers versus nondippers). COER-Verapamil Study Group. Am J Cardiol 1997, 80:469–74.

    Article  PubMed  CAS  Google Scholar 

  23. Carter BL: Optimizing delivery systems to tailor pharmacotherapy to cardiovascular circadian events. Am J Health Syst Pharm 1998, 55:S17-S23. Discusses the importance of a better blood pressure control, especially during early morning hours, and the relative inability of some conventional antihypertensive agents to do this optimally. Emphasizes the importance to tailor pharmacotherapy to cardiovascular circadian events, and described the design, pharmacokinetics and pharmacodynamics as well as the clinical experience obtained s far with the new chronotherapeutic formulation of verapamil COER.

    PubMed  Google Scholar 

  24. Anwar YA, White WB: Chronotherapeutics for cardiovascular disease. Drugs 1998, 55:631–643. Describes the relationship between time in terms of circadian variation and disease using various examples. Makes the point of the timing of administration versus the effects of conventional (nonchronotherapeutic) formulations of antihypertensive agents. Presents the results of the different clinical studies done with the new chronotherapeutic formulation verapamil (Chronovera or Covera HS).

    Article  PubMed  CAS  Google Scholar 

  25. Palatini P, Racioppa A, Raule A, et al.: Effect of timing of administration on the plasma ACE inhibitor activity and the antihypertensive effect of quinapril. Clin Pharmacol Ther 1992, 52:378–383.

    Article  PubMed  CAS  Google Scholar 

  26. Greminger P, Suter PM, Holm D, et al.: Morning versus evening administration of nifedipine gastrointestinal therapeutic system in the management of essential hypertension. Clin Investig 1994, 72:864–869.

    Article  PubMed  CAS  Google Scholar 

  27. Lemmer B: Differential effects of antihypertensive drugs on circadian rhythm in blood pressure from the chronobiological point of view. Blood Press Monit 1996, 1:161–169.

    PubMed  Google Scholar 

  28. Fogari R, Malocco E, Tettamanti F, et al.: Evening versus morning isradipine sustained release in essential hypertension: a double-blind study with 24-hour ambulatory monitoring. Br J Clin Pharmacol 1993, 35:51–54.

    PubMed  CAS  Google Scholar 

  29. Lemmer B, Sasse U, Witte K, et al.: Pharmacokinetics and cardiovascular effects of a new sustained-release formulation of diltiazem [abstract]. Arch Pharmacol 1994, 349S:R141.

    Google Scholar 

  30. Meilhac B, Mallion JM, Carre A, et al.: Étude de l’influence de l’horaire de la prise sur l’effet antihypertenseur et la tolérance de la nitrendipine chez des patients hypertendus essentiels légers à modérés. Therapie 1992, 47:205–210.

    PubMed  CAS  Google Scholar 

  31. Umeda T, Naomi S, Iwaoka K, et al.: Timing of administration of am antihypertensive drug in the treatment of essential hypertension. Hypertension 1994, 23:1211–1214.

    Google Scholar 

  32. Palatini P, Mos L, Mormino P, et al.: Effect of evening versus morning benazepril on 24-hour blood pressure: a comparative study with continuous intraarterial monitoring. Int J Clin Pharmacol Ther 1993, 31:295–300.

    CAS  Google Scholar 

  33. Witte K, Weisser K, Neubeck M, et al.: Cardiovascular effects, pharmacokinetics, and converting enzyme inhibition o enalapril after morning versus evening administration. Clin Pharmacol Ther 1993, 54:177–186.

    Article  PubMed  CAS  Google Scholar 

  34. Conte G, Rigon N, Perrone A: Application of chronotherapy to cardiovascular disease. Recenti Prog Med 1998, 89:465–469.

    PubMed  CAS  Google Scholar 

  35. Kario K, Matsuo T, Kobayashi H, et al.: Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients: advanced silent cerebrovascular damage in extreme dippers. Hypertension 1996, 27:130–135.

    PubMed  CAS  Google Scholar 

  36. Burt VL, Whelton P, Roccella EJ, et al.: Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995, 25:305–313.

    PubMed  CAS  Google Scholar 

  37. Chockalingam A, Fodor JG: Treatment of raised blood pressure in the population: the Canadian experience. Am J Hypertens 1998, 11:747–749.

    Article  PubMed  CAS  Google Scholar 

  38. Mancia G, Cattaneo BM, Omboni S, et al.: Clinical benefits of a consistent reduction in blood pressure. J Hypertens Suppl 1998, 16:S35-S39. Emphasizes the importance of a consistent reduction in blood pressure in light of a reduction on morbidity and mortality. However, the authors suggest that we should use antihypertensive agents that confer 24-hour blood pressure control and therefore, possess a long duration of action. Presents the performance of several antihypertensive agents based on different end points (eg, trough:peak ratio, ambulatory blood presssure).

    PubMed  CAS  Google Scholar 

  39. WHO/ISH Guidelines Sub-Committee. Guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens 1993, 11:905–918.

    Article  Google Scholar 

  40. Zannad F, Matzinger A, Larché J: Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am J Hypertens 1996, 9:633–643.

    Article  PubMed  CAS  Google Scholar 

  41. Lefebvre J, Poirier L, Archambault F, et al.: Comparative effects of felodipine ER, amlodipine and nifedipine GITS on 24h blood pressure control and trough to peak ratios in mild to moderate ambulatory hypertension: a forced titration study. Can J Cardiol 1998, 14:682–688.

    PubMed  CAS  Google Scholar 

  42. Lacourciere Y, Poirier L, Lefebvre J, et al.: Clinical efficacy of force titrated doses of diltiazem extended-release: a placebo-controlled study. Am J Hypertens 1995, 8:282–286.

    Article  PubMed  CAS  Google Scholar 

  43. Lacourciere Y, Lefebvre J, Poirier L, et al.: Treatment of ambulatory hypertensives with nebivolol or hydrochlorothiazide alone and in combination: a randomized, double-blind, placebo-controlled, factorial-design trial. Am J Hypertens 1994, 7:137–45.

    PubMed  CAS  Google Scholar 

  44. Lacourciere Y, Poirier L, Dion D, et al.: Antihypertensive effect of isradipine administered once or twice daily on ambulatory blood pressure. Am J Cardiol 1990, 65:467–72.

    Article  PubMed  CAS  Google Scholar 

  45. Black HR, Elliott WJ, Neaton JD, et al.: Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial. Control Clin Trials 1998, 19:370–390. The description of the design, the methodoogy, and the end points of this important study are presented. The CONVINCE study is the first major trial to measure the impact of using chronotherapeutics in comparison with conventional antihypertensive agents on a multitude of cardiovascular end points.

    Article  PubMed  CAS  Google Scholar 

  46. White WB: A chronotherapeutic approach to the management of hypertension. Am J Hypertens 1996, 9:29S-33S.

    PubMed  CAS  Google Scholar 

  47. White WB, Black HR, Weber MA, et al.: Comparison of effects of controlled onset extended release verapamil at bedtime and nifedipine gastrointestinal therapeutic system on arising on early morning blood pressure, heart rate, and the heart rate-blood pressure product. Am J Cardiol 1998, 81:424–431.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unité de recherche sur l’hypertension, CHUQ pavillon CHUL (S-122), 2705 boul. Laurier, G1V 4G2, Ste-Foy, Québec, Canada

    Luc Poirier MSc, Jean Lefebvre MSc & Yves Lacourciere MD

Authors
  1. Luc Poirier MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean Lefebvre MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yves Lacourciere MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Poirier, L., Lefebvre, J. & Lacourciere, Y. Chronotherapeutics: Are there meaningful differences among antihypertensive drugs?. Current Science Inc 1, 320–327 (1999). https://doi.org/10.1007/s11906-999-0040-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-999-0040-7

Keywords

Search

Navigation